| Drug / Therapy | FT576 |
| Indication | multiple myeloma |
| Decision Type | PDUFA |
| Conditions | multiple myeloma |
| Interventions | FT576 |
Fate Therapeutics (FATE) operates in the Cell Therapy sector. The current BTS Score is 34 (Grade: F).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The PDUFA date for FT576 by Fate Therapeutics (FATE) is scheduled for November 5, 2026. This is the target date for the FDA to make a decision on this application.
FT576 is being developed by Fate Therapeutics for the treatment of multiple myeloma. It is under FDA review.
If FT576 receives FDA approval, Fate Therapeutics (FATE) would be able to market the drug in the United States for multiple myeloma. This typically leads to significant stock price movement for biotech companies. Investors should monitor the PDUFA date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for FATE on DilutionWatch at dilutionwatch.com/stock/FATE.html.
You can view the full BiotechSign company profile for Fate Therapeutics (FATE) at biotechsign.com/app/company/FATE, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSign is not a registered investment advisor.